Drug Profile
Research programme: anti-hypercholesterolaemia monoclonal antibody - Lundbeck Seattle BioPharmaceuticals Inc
Alternative Names: ALD 306Latest Information Update: 24 Feb 2020
Price :
$50
*
At a glance
- Originator Alder Biopharmaceuticals
- Developer Lundbeck Seattle BioPharmaceuticals Inc.
- Class Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypercholesterolaemia
Most Recent Events
- 22 Oct 2019 Alder Biopharmaceuticals has been acquired by Lundbeck A/S
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypercholesterolaemia in USA (Parenteral)
- 19 Apr 2012 Preclinical trials in Hypercholesterolaemia in USA (Parenteral)